Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Kimberly-Clark Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $31.3B | |
|---|---|---|
| Revenue (ttm) | 16.6B | |
| Net income (ttm) | 2B | |
| EPS (ttm) | $5.86 | |
| Shares out | 332.6M | |
| P/E (trailing) | 18.5x | |
| P/E (forward) | 13.1x | |
| Dividend | $5.12 (4.73%) | |
| Volume | 2,561,172 | |
| Beta | 0.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $19.44B | $20.18B | $17.15B | $16.81B | $16.45B | -4.1% |
| Gross profit | $5.99B | $6.22B | $6.27B | $6.29B | $5.92B | -0.3% |
| Operating income | $2.56B | $2.68B | $1.93B | $2.70B | $2.35B | -2.1% |
| Net income | $1.81B | $1.93B | $1.76B | $2.55B | $2.02B | +2.7% |
| EPS (diluted) | $5.35 | $5.72 | $5.21 | $7.55 | $6.07 | +3.2% |
| EBITDA | $3.25B | $3.38B | $2.34B | $3.98B | $3.11B | -1.1% |
| R&D | $269.0M | $292.0M | $303.0M | $328.0M | $326.0M | +4.9% |
| SG&A | $3.40B | $3.58B | $3.88B | $4.31B | $3.53B | +0.9% |
Recent company headlines from major financial publishers.
In the base case, Kimberly-Clark delivers steady turnaround execution, with revenue expanding 0.96% in FY2026 ($16,605M) and 2.65% in FY2027 ($17,045M). Operating margins widen through FY2030 as the 2024 Transformation Initiative offsets input inflation and normalizes supply chain operations, supporting Fair value at $121.76.
In the bull case, premium innovation tiering accelerates volume-plus-mix expansion across Huggies, Kleenex, and Kotex, while the resolution of false China quality allegations drives a sharper recovery in International Personal Care. Gross productivity savings exceed baseline cost inflation, expanding operating margins toward peer benchmarks and generating robust free cash flow to accelerate debt reduction and shareholder returns, supporting valuation toward $163.21.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 5.7% | $135 | $141 | $147 | $154 | $163 |
| 6.2% | $124 | $128 | $133 | $138 | $145 |
| 6.7% | $115 | $118 | $122 | $126 | $131 |
| 7.2% | $107 | $110 | $113 | $116 | $120 |
| 7.7% | $101 | $103 | $105 | $108 | $111 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |